+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of acute DVT with the low molecular weight heparin reviparin Results of the CORTES-Study



Treatment of acute DVT with the low molecular weight heparin reviparin Results of the CORTES-Study



Blood 94(10 SUPPL 1 PART 1): 30a, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035980736

Download citation: RISBibTeXText


Related references

Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study. Zeitschrift für Kardiologie 86(8): 581-591, 1997

Low molecular weight heparin, reviparin after PTCA: Results of a randomized, double-blind, standard heparin and placebo controlled multicenter study (REDUCE Trial). Zeitschrift fuer Kardiologie 86(8): 581-591, 1997

Reviparin in the treatment of acute DVT Effects on the phlebographic outcome Results of the CORTES-trial. Haemostasis 30(Suppl 1): 66, 2000

Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: preliminary results of an ongoing study. Cardiovascular and Interventional Radiology 21(5): 375-379, 1998

Low Molecular weight heparin, reviparin, in prevention of restenosis after PTCA Results of the reduce trial. Journal of the American College of Cardiology 27(2 SUPPL A): 113A, 1996

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE Trial). Journal of the American College of Cardiology 28(6): 1437-1443, 1996

Low molecular weight heparin, reviparin, in prevention of restenosis after percutaneous transluminal coronary angioplasty Results of the REDUCE trial. European Heart Journal 17(ABSTR SUPPL ): 119, 1996

Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. Arthroscopy 17(4): 393-399, 2001

Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin). Transplantation 72(2): 209-215, 2001

Pharmacokinetic profile of a low-molecular weight heparin (Reviparin) in pregnant patients: A prospective cohort study. Thrombosis Research 98(2): 133-138, 2000

Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293(4): 427-435, 2005

Crossreactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thrombosis and Haemostasis 72(4): 644-645, 1994

Reviparin sodium - a new low molecular weight heparin. Expert Opinion on PharmacoTherapy 3(2): 173-182, 2002

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 80(4): 935-940, 1989

Low molecular weight heparin: immediate therapy of stroke? A discussion of the study by Kay et al.: Low molecular weight heparin for treatment of acute ischemic stroke. Der Nervenarzt 67(10): 886-887, 1996